Why invest in Chundsell Medicals

• By providing new and personalized information, Chundsell is actively involved in the radical transformation of prostate cancer healthcare with its Prostatype® Test System (PrTS)
• Significant market opportunity in prostate cancer market segment: 630 MEUR annually
• Studies indicate over‐ and undertreatment of 7 out of 10 prostate cancer patients
• Ready for market: CE‐approved, IP protected and ISO 13485:2012 certified
• Clinical studies with early adopters validates PrTS – concluded and ongoing studies
• First commercial installation of PrTS expected second half of 2016
• Highly scalable business model with recurring sales
• Chundsell is improving patients’ quality of life while reducing healthcare costs:
•      combining genetic testing using stem cell gene signatures,
•      with advanced data analysis (unique proprietary patient database and algorithm),
•      evolution towards personalized medicine in prostate cancer healthcare,
• Chundsell Medicals has and will conduct all its activities based on good ethics for the patients.

‍Chundsell Medicals seeks 20.0 MSEK at a pre‐money valuation of 89.7 MSEK, entailing 18.2% ownership and 16.5% ownership fully diluted. The proceeds are intended to support and accelerate our commercialisation process.